Analyst Group Interview Genetic Analysis' CEO Ronny Hermansen скачать в хорошем качестве

Analyst Group Interview Genetic Analysis' CEO Ronny Hermansen

Analyst Group Interview Ronny Hermansen CEO of Genetic Analysis in connnection to the company's Q4-report 2025. 00:07 - For those who may not yet be familiar with Genetic Analysis, could you provide a brief introduction to the company, its core activities, and the markets in which you operate? 01:28 - You recently published your quarterly report for Q4-25. How would you summarize the quarter? 04:32 - Reagent kit sales continue to be the key growth driver, while service revenues declined during the quarter. How should investors view the mix going forward, and do you expect reagent kit sales to remain the primary growth engine? 06:15 - The MHI GutHealth test has now been on the market for a few months and generated sales during Q4-25. How has the commercial rollout progressed, and what feedback are you receiving from the market so far? 08:35 - How do you view the balance in 2026 between investing to accelerate growth, particularly around new product launches and U.S. commercialization, and maintaining cost control to move closer to sustainable profitability? 09:41 - Lastly, what would you like to highlight as particularly interesting for an investor to monitor regarding Genetic Analysis during 2026? Read more here: https://analystgroup.se/bolag/genetic...